Raagini Jawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raagini Jawa has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Margaret Shang
Center for Research on Health Care, Division of General Internal Medicine, Department of Medicine University of Pittsburgh, PA, USA
10 shared publicationsJane M. Liebschutz
Center for Research on Health Care, Division of General Internal Medicine, Department of Medicine University of Pittsburgh, PA, USA
7 shared publicationsGary McMurtrie
Center for Research on Healthcare, University of Pittsburgh School of Medicine, 3609 Forbes Ave, Pittsburgh, PA, 15213, USA
4 shared publicationsStephen Murray
Grayken Center for Addiction, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, 801 Massachusetts Avenue, Second Floor, Boston, MA, 02118, USA
4 shared publicationsCristina Murray-Krezan
Center for Research on Healthcare, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, 3609 Forbes Ave, 2nd floor, Pittsburgh, PA, 15213, USA
3 shared publicationsIlana Hull
Center for Research on Health Care, Division of General Internal Medicine, Department of Medicine University of Pittsburgh, PA, USA
3 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by SAGE Publications in Substance use & addiction journal
“You Do What You Have To Do”: Risk Environments in Xylazine Wound Care
Background: Xylazine, a veterinary sedative, has become a prevalent adulterant in the unregulated opioid supply and can lead to chronic ulcerative wounds among people who use drugs (PWUD). Without regular care, these wounds can progress and result in infectious and limb-threatening complications. Despite this, PWUD face many barriers to wound self-management and medical treatment. Using the Rhodes’ Risk Environment framework, we investigated factors that influence wound care practices and healing among PWUD with xylazine-associated wounds in Pittsburgh, Pennsylvania. Methods: From March to April 2024, we conducted semi-structured interviews with 20 PWUD with at least one xylazine-associated wound and past-90-day xylazine exposure confirmed by laboratory urine testing or self-reported xylazine test strip results. Using content analysis guided by the Rhodes’ Risk Environment framework, we categorized individual-level, micro-level, and macro-level factors influencing wound care and outcomes and defined care practices shaped by these factors. Results: At the individual level, xylazine-associated wound care and healing were shaped by participant knowledge, prior experience, and resourcefulness. Pain, withdrawal, ongoing substance use, and emotional responses like fear and guilt also strongly influenced wound care practices and care-seeking behaviors. At micro and macro levels, multiple factors across the physical, economic, social, and health care environments further impacted wound outcomes, including environmental hazards, resource scarcity (eg, wound supply availability and affordability), health care and public stigma, social support networks, punitive policies, and quality of medical care and access. Conclusion: Overall, xylazine-associated wound care practices and healing are modified by various individual and structural factors within the risk environment that may lead to disruption in consistent wound care. To improve clinical outcomes, health care systems should prioritize low-barrier strategies that minimize gaps in care, support timely reentry to facilitate wound self-management, and foster continued engagement by addressing the underlying factors that drive treatment hesitation and interruptions.
- 8 October 2026
- Published by SAGE Publications in Substance use & addiction journal
Open Access“You Do What You Have To Do”: Risk Environments in Xylazine Wound Care
Background: Xylazine, a veterinary sedative, has become a prevalent adulterant in the unregulated opioid supply and can lead to chronic ulcerative wounds among people who use drugs (PWUD). Without regular care, these wounds can progress and result in infectious and limb-threatening complications. Despite this, PWUD face many barriers to wound self-management and medical treatment. Using the Rhodes’ Risk Environment framework, we investigated factors that influence wound care practices and healing among PWUD with xylazine-associated wounds in Pittsburgh, Pennsylvania. Methods: From March to April 2024, we conducted semi-structured interviews with 20 PWUD with at least one xylazine-associated wound and past-90-day xylazine exposure confirmed by laboratory urine testing or self-reported xylazine test strip results. Using content analysis guided by the Rhodes’ Risk Environment framework, we categorized individual-level, micro-level, and macro-level factors influencing wound care and outcomes and defined care practices shaped by these factors. Results: At the individual level, xylazine-associated wound care and healing were shaped by participant knowledge, prior experience, and resourcefulness. Pain, withdrawal, ongoing substance use, and emotional responses like fear and guilt also strongly influenced wound care practices and care-seeking behaviors. At micro and macro levels, multiple factors across the physical, economic, social, and health care environments further impacted wound outcomes, including environmental hazards, resource scarcity (eg, wound supply availability and affordability), health care and public stigma, social support networks, punitive policies, and quality of medical care and access. Conclusion: Overall, xylazine-associated wound care practices and healing are modified by various individual and structural factors within the risk environment that may lead to disruption in consistent wound care. To improve clinical outcomes, health care systems should prioritize low-barrier strategies that minimize gaps in care, support timely reentry to facilitate wound self-management, and foster continued engagement by addressing the underlying factors that drive treatment hesitation and interruptions.
- Open Access
- 10 July 2026
- Published by SAGE Publications in Substance use & addiction journal
Reimagining Methadone Clinics: A Case For Integrating Risk Reduction to Address the Complex Realities of Opioid Use Disorder
Background: Opioid treatment programs (OTPs), the only outpatient settings authorized to dispense methadone for opioid use disorder in the United States, often operate within compliance-focused frameworks that do not reflect the complex realities of substance use or the needs of many patients with the evolving opioid crisis. Given their unique infrastructure, OTPs are well-positioned to provide risk reduction services including naloxone, wound care supplies, and other safer use tools. Objectives: Describe the implementation and early outcomes of a pragmatic pilot program integrating safer use kit distribution within a large OTP in Western Pennsylvania. Methods: Our team worked with the OTP to develop a workflow for safer use kit distribution. Staff offered interested patients a menu of safer use kits from which they could select up to one of each kit type. Prepackaged kits included fentanyl/xylazine test strips and safer injection, smoking, snorting, and wound care supplies. Kit distribution was tracked over a thirteen-month period. Postimplementation, we sampled patient-facing OTP staff on their perspectives of the program. Results: From November 2024 to November 2025, 643 kits were distributed during 266 encounters with 142 unique patients. High-demand items included test strips and safer smoking kits. Staff reported improved patient engagement, reduced stigma, and stronger therapeutic relationships after implementing on-site kits. Conclusion: Integrating safer use kits into OTPs is both feasible and impactful, demonstrating consistent patient uptake and positive staff perceptions. These findings suggest such models have the potential to support more inclusive, patient-centered care, though future research is needed to determine downstream effects on retention, safety, and clinical outcomes.
- 10 July 2026
- Published by SAGE Publications in Substance use & addiction journal
Open AccessReimagining Methadone Clinics: A Case For Integrating Risk Reduction to Address the Complex Realities of Opioid Use Disorder
Background: Opioid treatment programs (OTPs), the only outpatient settings authorized to dispense methadone for opioid use disorder in the United States, often operate within compliance-focused frameworks that do not reflect the complex realities of substance use or the needs of many patients with the evolving opioid crisis. Given their unique infrastructure, OTPs are well-positioned to provide risk reduction services including naloxone, wound care supplies, and other safer use tools. Objectives: Describe the implementation and early outcomes of a pragmatic pilot program integrating safer use kit distribution within a large OTP in Western Pennsylvania. Methods: Our team worked with the OTP to develop a workflow for safer use kit distribution. Staff offered interested patients a menu of safer use kits from which they could select up to one of each kit type. Prepackaged kits included fentanyl/xylazine test strips and safer injection, smoking, snorting, and wound care supplies. Kit distribution was tracked over a thirteen-month period. Postimplementation, we sampled patient-facing OTP staff on their perspectives of the program. Results: From November 2024 to November 2025, 643 kits were distributed during 266 encounters with 142 unique patients. High-demand items included test strips and safer smoking kits. Staff reported improved patient engagement, reduced stigma, and stronger therapeutic relationships after implementing on-site kits. Conclusion: Integrating safer use kits into OTPs is both feasible and impactful, demonstrating consistent patient uptake and positive staff perceptions. These findings suggest such models have the potential to support more inclusive, patient-centered care, though future research is needed to determine downstream effects on retention, safety, and clinical outcomes.
- Open Access
- 3 July 2026
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 21 (1)
Perspectives on harm reduction kit implementation in heterogeneous outpatient clinics
The evolving U.S. drug market has fueled a public health crisis with rising drug use-associated morbidity and mortality, revealing a mismatch between current abstinence-based addiction care and the needs of people who use drugs (PWUD) to access evidence-based harm reduction services (HRS). Co-locating HRS into outpatient clinics could reduce mortality and improve clinical outcomes. We investigated barriers and facilitators of HRS implementation through kit distribution at three heterogenous outpatient addiction clinics using pre- and post-implementation focus groups. Using a qualitative description approach, we conducted 1-hour virtual focus groups and individual interviews with clinic staff and providers both pre- and post-implementation of kit distribution. Interview guides were based on the Consolidated Framework for Implementation Research to assess anticipated and actual implementation barriers and facilitators. Interviews were analyzed using thematic analysis. Five providers and six staff participated in pre-implementation data collection. Dominant themes pre-implementation included participant enthusiasm for HRS integration and anticipated barriers of personal knowledge and external stigma against PWUD. Six providers and five staff participated post-implementation. Participants reported successful kit implementation with few actual barriers, though external stigma at the individual, health system, and community levels, along with issues related to patient use and interactions with child protective services, law enforcement, and pharmacies, occasionally disrupted the process. The lack of sustainable funding for supplies and labor emerged as a primary concern for long-term sustainability, with clinics actively seeking alternative funding sources. Implementation of HRS in outpatient addiction clinics was well-received by providers and staff and supported by pre-implementation trainings, site champions, and favorable implementation environments. Further efforts are needed to reduce stigma in the greater community and achieve sustainable funding for HRS.
- 3 July 2026
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 21 (1)
Open AccessPerspectives on harm reduction kit implementation in heterogeneous outpatient clinics
The evolving U.S. drug market has fueled a public health crisis with rising drug use-associated morbidity and mortality, revealing a mismatch between current abstinence-based addiction care and the needs of people who use drugs (PWUD) to access evidence-based harm reduction services (HRS). Co-locating HRS into outpatient clinics could reduce mortality and improve clinical outcomes. We investigated barriers and facilitators of HRS implementation through kit distribution at three heterogenous outpatient addiction clinics using pre- and post-implementation focus groups. Using a qualitative description approach, we conducted 1-hour virtual focus groups and individual interviews with clinic staff and providers both pre- and post-implementation of kit distribution. Interview guides were based on the Consolidated Framework for Implementation Research to assess anticipated and actual implementation barriers and facilitators. Interviews were analyzed using thematic analysis. Five providers and six staff participated in pre-implementation data collection. Dominant themes pre-implementation included participant enthusiasm for HRS integration and anticipated barriers of personal knowledge and external stigma against PWUD. Six providers and five staff participated post-implementation. Participants reported successful kit implementation with few actual barriers, though external stigma at the individual, health system, and community levels, along with issues related to patient use and interactions with child protective services, law enforcement, and pharmacies, occasionally disrupted the process. The lack of sustainable funding for supplies and labor emerged as a primary concern for long-term sustainability, with clinics actively seeking alternative funding sources. Implementation of HRS in outpatient addiction clinics was well-received by providers and staff and supported by pre-implementation trainings, site champions, and favorable implementation environments. Further efforts are needed to reduce stigma in the greater community and achieve sustainable funding for HRS.
- Open Access
- 17 June 2026
- Published by Springer Nature in Harm Reduction Journal
Navigating an unpredictable supply: lived experiences of xylazine exposure among people who use drugs
As xylazine-adulterated opioids become more prevalent in the U.S., people who use drugs (PWUD) face growing risks from sedation, withdrawal, and wounds. This study explores PWUD perceptions on recognizing xylazine exposure including its physical effects and clinical harms and how these factors shape their drug use practices. In August 2023, we surveyed adult PWUD clients reporting at least one past-year drug use-related wound across three Massachusetts syringe service programs with high xylazine prevalence. We compared demographics, drug use factors, physical effects, and clinical symptoms between those with and without self-reported past-90-day xylazine exposure and conducted content analysis of open-ended responses. Of the 171 respondents, 80% (n = 136) reported past-90-day xylazine exposure. The majority of respondents were male, white, non-Hispanic, and aged 36-45 years, with no significant differences by xylazine exposure. Xylazine-exposed participants commonly reported sedation (77%), loss of consciousness (52%), and wounds (91%). Most participants were afraid and frustrated, seeing xylazine as an unwanted contaminant but were often unable to avoid it due to financial constraints, withdrawal symptoms, and limited alternative options. Syringe service program clients in Massachusetts commonly reported xylazine-adulterated fentanyl exposure, recognized through heavy sedation and skin wounds. Their experiences highlight the urgent need for real-time xylazine detection, safer supply, overdose and sedation risk mitigation, and improved wound prevention and care.
- 17 June 2026
- Published by Springer Nature in Harm Reduction Journal
Open AccessNavigating an unpredictable supply: lived experiences of xylazine exposure among people who use drugs
As xylazine-adulterated opioids become more prevalent in the U.S., people who use drugs (PWUD) face growing risks from sedation, withdrawal, and wounds. This study explores PWUD perceptions on recognizing xylazine exposure including its physical effects and clinical harms and how these factors shape their drug use practices. In August 2023, we surveyed adult PWUD clients reporting at least one past-year drug use-related wound across three Massachusetts syringe service programs with high xylazine prevalence. We compared demographics, drug use factors, physical effects, and clinical symptoms between those with and without self-reported past-90-day xylazine exposure and conducted content analysis of open-ended responses. Of the 171 respondents, 80% (n = 136) reported past-90-day xylazine exposure. The majority of respondents were male, white, non-Hispanic, and aged 36-45 years, with no significant differences by xylazine exposure. Xylazine-exposed participants commonly reported sedation (77%), loss of consciousness (52%), and wounds (91%). Most participants were afraid and frustrated, seeing xylazine as an unwanted contaminant but were often unable to avoid it due to financial constraints, withdrawal symptoms, and limited alternative options. Syringe service program clients in Massachusetts commonly reported xylazine-adulterated fentanyl exposure, recognized through heavy sedation and skin wounds. Their experiences highlight the urgent need for real-time xylazine detection, safer supply, overdose and sedation risk mitigation, and improved wound prevention and care.
- Open Access
Xylazine test strip utilization among pregnant and postpartum women with opioid use disorder: A pilot study
Introduction: The emergence of xylazine, a veterinary alpha‐2 and kappa opioid receptor agonist, as an adulterant in illicitly manufactured fentanyl has created new challenges and risks for pregnant people who use unregulated opioids. Xylazine test strips (XTSs) have been proposed as a harm reduction strategy, but their use has not been studied among pregnant and postpartum populations. The goals of this study were to assess the feasibility, acceptability, and efficacy of a novel Perinatal XTS intervention aimed at reducing xylazine exposure and associated harms. Methods: Pregnant and postpartum women with opioid use disorder and high risk of ongoing unregulated opioid use were recruited from inpatient units of a high‐volume maternity hospital in western Pennsylvania. Participants engaged in a standardized educational session about xylazine and XTS and then were given five XTS kits. Over a 2‐month period, participants were asked to complete a real‐time survey when they used an XTS to report test results and any associated drug use behavior change. All participants were asked to participate in an end‐of‐study survey and a semi‐structured interview about their experiences with Perinatal XTS. Results: A total of 50 participants were enrolled, completed the education session, and accepted the XTS kits. Most participants were concerned about the potential impacts of xylazine on pregnancy and neonatal outcomes. Seventeen participants submitted a total of 71 real‐time surveys after using XTS to test drug samples. In the majority of cases, a positive result prompted behavioral change. Qualitative interviews with participants revealed six major themes: (1) Xylazine and XTS education was highly acceptable. (2) Desire for additional education related to xylazine. (3) XTS distribution and use were highly acceptable. (4) Impact of XTS on behavior change varied based on participant circumstances. (5) Concerns related to xylazine's impact on maternal health and treatment. (6) Concerns related to xylazine's impact on fetal and neonatal health. Conclusion: Findings from this pilot study demonstrate that Perinatal XTS, a harm‐reduction intervention combining xylazine and XTS education and XTS kit distribution, is highly feasible to deliver, is acceptable among pregnant and postpartum women cared for in an obstetric healthcare setting, and has the potential to reduce risk‐related behaviors.
Open AccessXylazine test strip utilization among pregnant and postpartum women with opioid use disorder: A pilot study
Introduction: The emergence of xylazine, a veterinary alpha‐2 and kappa opioid receptor agonist, as an adulterant in illicitly manufactured fentanyl has created new challenges and risks for pregnant people who use unregulated opioids. Xylazine test strips (XTSs) have been proposed as a harm reduction strategy, but their use has not been studied among pregnant and postpartum populations. The goals of this study were to assess the feasibility, acceptability, and efficacy of a novel Perinatal XTS intervention aimed at reducing xylazine exposure and associated harms. Methods: Pregnant and postpartum women with opioid use disorder and high risk of ongoing unregulated opioid use were recruited from inpatient units of a high‐volume maternity hospital in western Pennsylvania. Participants engaged in a standardized educational session about xylazine and XTS and then were given five XTS kits. Over a 2‐month period, participants were asked to complete a real‐time survey when they used an XTS to report test results and any associated drug use behavior change. All participants were asked to participate in an end‐of‐study survey and a semi‐structured interview about their experiences with Perinatal XTS. Results: A total of 50 participants were enrolled, completed the education session, and accepted the XTS kits. Most participants were concerned about the potential impacts of xylazine on pregnancy and neonatal outcomes. Seventeen participants submitted a total of 71 real‐time surveys after using XTS to test drug samples. In the majority of cases, a positive result prompted behavioral change. Qualitative interviews with participants revealed six major themes: (1) Xylazine and XTS education was highly acceptable. (2) Desire for additional education related to xylazine. (3) XTS distribution and use were highly acceptable. (4) Impact of XTS on behavior change varied based on participant circumstances. (5) Concerns related to xylazine's impact on maternal health and treatment. (6) Concerns related to xylazine's impact on fetal and neonatal health. Conclusion: Findings from this pilot study demonstrate that Perinatal XTS, a harm‐reduction intervention combining xylazine and XTS education and XTS kit distribution, is highly feasible to deliver, is acceptable among pregnant and postpartum women cared for in an obstetric healthcare setting, and has the potential to reduce risk‐related behaviors.
- 17 March 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (3) , 628-638
In Support of Harm Reduction Supply Distribution Via Vending Machines: Position Statement of AMERSA, Inc.
Background: Harm reduction services fulfill a critical need in reducing the negative consequences associated with the overdose crisis. However, many current evidence-based harm reduction services—such as syringe service programs—have access barriers including limited hours or the need for face-to-face interactions to help serve people who use drugs (PWUD). Issue: To complement such traditional services, overcome barriers, and bridge gaps, harm reduction vending machines (HRVMs) are increasingly being used to offer PWUD low-barrier, 24-hour access to harm reduction supplies, such as naloxone, drug-checking strips, condoms, and more. Evidence from around the world, and more recently in the United States, demonstrates that HRVMs not only provide anonymous no- or low-cost supplies to PWUD, but also do so in ways that overcome key barriers such as stigma, cost, and transportation, while also increasing accessibility and acceptability among PWUD. Perhaps most notably, HRVMs can do all of this while remaining cost-efficient, highly accessible, and adaptable to community needs. Recommendations: Accordingly, the Association for Multidisciplinary Education and Research in Substance Use and Addiction supports funding and research for the broader application of HRVMs, alongside the creation of national implementation guidance and federal and state policy alignment, to ensure that communities across the United States can access these crucial harm reduction services.
- 17 March 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (3) , 628-638
In Support of Harm Reduction Supply Distribution Via Vending Machines: Position Statement of AMERSA, Inc.
Background: Harm reduction services fulfill a critical need in reducing the negative consequences associated with the overdose crisis. However, many current evidence-based harm reduction services—such as syringe service programs—have access barriers including limited hours or the need for face-to-face interactions to help serve people who use drugs (PWUD). Issue: To complement such traditional services, overcome barriers, and bridge gaps, harm reduction vending machines (HRVMs) are increasingly being used to offer PWUD low-barrier, 24-hour access to harm reduction supplies, such as naloxone, drug-checking strips, condoms, and more. Evidence from around the world, and more recently in the United States, demonstrates that HRVMs not only provide anonymous no- or low-cost supplies to PWUD, but also do so in ways that overcome key barriers such as stigma, cost, and transportation, while also increasing accessibility and acceptability among PWUD. Perhaps most notably, HRVMs can do all of this while remaining cost-efficient, highly accessible, and adaptable to community needs. Recommendations: Accordingly, the Association for Multidisciplinary Education and Research in Substance Use and Addiction supports funding and research for the broader application of HRVMs, alongside the creation of national implementation guidance and federal and state policy alignment, to ensure that communities across the United States can access these crucial harm reduction services.
- Open Access
- 25 January 2026
- Published by Springer Nature in Research Square
Perspectives on Harm Reduction Kit Implementation in Heterogeneous Outpatient Clinics
Background: The evolving U.S. drug market has fueled a public health crisis with rising drug use-associated morbidity and mortality, revealing a mismatch between current abstinence-based addiction care and the needs of people who use drugs (PWUD) to access evidence-based harm reduction services (HRS). Co-locating HRS into outpatient clinics could reduce mortality and improve clinical outcomes. We investigated barriers and facilitators of HRS implementation through kit distribution at three heterogenous outpatient addiction clinics using pre- and post-implementation focus groups. Methods: We conducted qualitative description approach via 1-hour virtual focus groups and individual interviews with clinic staff and providers both pre- and post-implementation of kit distribution. Interview guides were based on the Consolidated Framework for Implementation Research to assess anticipated and actual implementation barriers and facilitators. Interviews were analyzed using thematic analysis. Results: Five providers and six staff participated in pre-implementation data collection. Dominant themes pre-implementation included participant enthusiasm for HRS integration and anticipated barriers of personal knowledge and external stigma against PWUD. Six providers and five staff participated post-implementation. Participants reported few actual barriers, of which external stigma and lack of funding for program sustainability were most prominent. Conclusions: Implementation of HRS in outpatient addiction clinics was well-received by providers and staff and supported by pre-implementation trainings, site champions, and favorable implementation environments. Further efforts are needed to reduce stigma in the greater community and achieve sustainable funding for HRS.
- 25 January 2026
- Published by Springer Nature in Research Square
Open AccessPerspectives on Harm Reduction Kit Implementation in Heterogeneous Outpatient Clinics
Background: The evolving U.S. drug market has fueled a public health crisis with rising drug use-associated morbidity and mortality, revealing a mismatch between current abstinence-based addiction care and the needs of people who use drugs (PWUD) to access evidence-based harm reduction services (HRS). Co-locating HRS into outpatient clinics could reduce mortality and improve clinical outcomes. We investigated barriers and facilitators of HRS implementation through kit distribution at three heterogenous outpatient addiction clinics using pre- and post-implementation focus groups. Methods: We conducted qualitative description approach via 1-hour virtual focus groups and individual interviews with clinic staff and providers both pre- and post-implementation of kit distribution. Interview guides were based on the Consolidated Framework for Implementation Research to assess anticipated and actual implementation barriers and facilitators. Interviews were analyzed using thematic analysis. Results: Five providers and six staff participated in pre-implementation data collection. Dominant themes pre-implementation included participant enthusiasm for HRS integration and anticipated barriers of personal knowledge and external stigma against PWUD. Six providers and five staff participated post-implementation. Participants reported few actual barriers, of which external stigma and lack of funding for program sustainability were most prominent. Conclusions: Implementation of HRS in outpatient addiction clinics was well-received by providers and staff and supported by pre-implementation trainings, site champions, and favorable implementation environments. Further efforts are needed to reduce stigma in the greater community and achieve sustainable funding for HRS.
- Open Access
- 13 January 2026
- Published by Springer Nature in Research Square
Navigating an Unpredictable Supply: Lived Experiences of Xylazine Exposure Among People Who Use Drugs
Background: As xylazine-adulterated opioids become more prevalent in the U.S., people who use drugs (PWUD) face growing risks from sedation, withdrawal, and wounds. This study explores PWUD perceptions on recognizing xylazine exposure including its physical effects and clinical harms and how these factors shape their drug use practices. Methods: In August 2023, we surveyed adult PWUD clients reporting at least one past-year drug use-related wound across three Massachusetts syringe service programs with high xylazine prevalence. We compared demographics, drug use factors, physical effects, and clinical symptoms between those with and without self-reported past-90-day xylazine exposure and conducted content analysis of open-ended responses. Results: Of the 171 respondents, 80% (n=136) reported past-90-day xylazine exposure. The majority of respondents were male, white, non-Hispanic, and aged 36-45 years, with no significant differences by xylazine exposure. Xylazine-exposed participants commonly reported sedation (77%), loss of consciousness (52%), and wounds (91%). Most participants were afraid and frustrated, seeing xylazine as an unwanted contaminant but were often unable to avoid it due to financial constraints, withdrawal symptoms, and limited alternative options. Conclusion: Syringe service program clients in Massachusetts commonly reported xylazine-adulterated fentanyl exposure, recognized through heavy sedation and skin wounds. Their experiences highlight the urgent need for real-time xylazine detection, safer supply, overdose and sedation risk mitigation, and improved wound prevention and care.
- 13 January 2026
- Published by Springer Nature in Research Square
Open AccessNavigating an Unpredictable Supply: Lived Experiences of Xylazine Exposure Among People Who Use Drugs
Background: As xylazine-adulterated opioids become more prevalent in the U.S., people who use drugs (PWUD) face growing risks from sedation, withdrawal, and wounds. This study explores PWUD perceptions on recognizing xylazine exposure including its physical effects and clinical harms and how these factors shape their drug use practices. Methods: In August 2023, we surveyed adult PWUD clients reporting at least one past-year drug use-related wound across three Massachusetts syringe service programs with high xylazine prevalence. We compared demographics, drug use factors, physical effects, and clinical symptoms between those with and without self-reported past-90-day xylazine exposure and conducted content analysis of open-ended responses. Results: Of the 171 respondents, 80% (n=136) reported past-90-day xylazine exposure. The majority of respondents were male, white, non-Hispanic, and aged 36-45 years, with no significant differences by xylazine exposure. Xylazine-exposed participants commonly reported sedation (77%), loss of consciousness (52%), and wounds (91%). Most participants were afraid and frustrated, seeing xylazine as an unwanted contaminant but were often unable to avoid it due to financial constraints, withdrawal symptoms, and limited alternative options. Conclusion: Syringe service program clients in Massachusetts commonly reported xylazine-adulterated fentanyl exposure, recognized through heavy sedation and skin wounds. Their experiences highlight the urgent need for real-time xylazine detection, safer supply, overdose and sedation risk mitigation, and improved wound prevention and care.
- 15 April 2025
- Published by SAGE Publications in Substance use & addiction journal
Building Multidisciplinary Consensus on Inpatient Xylazine Management through Clinical Protocols
The evolving unregulated drug supply in the United States has led to an unprecedented rise in xylazine-adulterated synthetic opioid use-related morbidity and mortality, of which Pennsylvania shoulders a disproportionate burden. People experiencing these xylazine harms who seek acute medical care require complex clinical management, multidisciplinary coordination, and appropriate linkage to outpatient care. We describe our experience leading a hospital-wide multidisciplinary xylazine workgroup from February to June 2024 to collaboratively develop time-sensitive clinical protocols on inpatient management of patients exposed to xylazine. Workgroup participants were organized into three subgroups: (1) toxicology screening and harm reduction; (2) withdrawal management; and (3) inpatient wound care management and linkage to outpatient wound care. We summarize our implementation process and clinical protocol recommendations of each subgroup and highlight important cross-cutting issues related to the changing drug supply, standardized patient and provider educational tools, care coordination, and next steps.
- 15 April 2025
- Published by SAGE Publications in Substance use & addiction journal
Building Multidisciplinary Consensus on Inpatient Xylazine Management through Clinical Protocols
The evolving unregulated drug supply in the United States has led to an unprecedented rise in xylazine-adulterated synthetic opioid use-related morbidity and mortality, of which Pennsylvania shoulders a disproportionate burden. People experiencing these xylazine harms who seek acute medical care require complex clinical management, multidisciplinary coordination, and appropriate linkage to outpatient care. We describe our experience leading a hospital-wide multidisciplinary xylazine workgroup from February to June 2024 to collaboratively develop time-sensitive clinical protocols on inpatient management of patients exposed to xylazine. Workgroup participants were organized into three subgroups: (1) toxicology screening and harm reduction; (2) withdrawal management; and (3) inpatient wound care management and linkage to outpatient wound care. We summarize our implementation process and clinical protocol recommendations of each subgroup and highlight important cross-cutting issues related to the changing drug supply, standardized patient and provider educational tools, care coordination, and next steps.